Privia Health (PRVA) Cash & Equivalents (2020 - 2026)

Privia Health has reported Cash & Equivalents for 7 years, with the latest figure at $412.2 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 5.66% year-over-year to $412.2 million in Q2 2026; TTM through Jun 2026 was $412.2 million, a 5.66% increase from a year earlier, with the FY2025 full-year figure at $479.7 million, down 2.33% from the prior year.
• Cash & Equivalents was $412.2 million for Q2 2026 at Privia Health, down from $419.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $491.1 million in Q4 2024, with the low at $292.2 million in Q2 2022.
• Average Cash & Equivalents over 5 years is $382.6 million, with a median of $388.4 million recorded in 2023.
• The largest YoY upside for Cash & Equivalents was 285.57% in 2022 against a maximum downside of 12.49% in 2022.
• Over 5 years, Cash & Equivalents stood at $348.0 million in 2022, then increased by 11.93% to $389.5 million in 2023, then increased by 26.09% to $491.1 million in 2024, then dropped by 2.33% to $479.7 million in 2025, then dropped by 14.07% to $412.2 million in 2026.
• The last three Cash & Equivalents figures came in at $412.2 million (Q2 2026), $419.5 million (Q1 2026), and $479.7 million (Q4 2025), per Business Quant data.